AKRO News and Press, Akero Therapeutics Inc. From 06/08/24

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations ...

2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...

2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...

2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws. If you suffered...

2024-05-15 09:00:12 ET Liisa Bayko from Evercore ISI issued a price target of $38.00 for AKRO on 2024-05-15 08:06:00. The adjusted price target was set to $38.00. At the time of the announcement, AKRO was trading at $20.3. The overall price target consensus is at $45.00 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 12, 2024) - Faruqi & Faruqi, LLP, a leading national secur...

2024-05-10 07:22:21 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program Akero Therapeutics announces pricing of stock offering to raise $319M Akero stock jumps as lead ...

-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to en...

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management wil...